Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era
Keywords:
Glioblastoma Multiforme, Hypofractioned radiotherapy, Covid-19, In-hospital contagion, Multimodal therapyAbstract
COVID-19 pandemic revolutionized the way in which cancer patients are treated worldwide. Regarding neuro-oncological patients, usually considered frail and with lower life-expectancy in respect to other oncological patients, the international scientific community had to urgently reorganize the treatment approach in order to minimize the risk of in-hospital contagious. For GBM patients, adjuvant treatments have been evaluated with even much more attention with regard to the expected efficacy. As a consequence, an hypofractioned radiotherapy regimen has been preferred in order to reduce the daily hospital accesses and, especially in pMGMT unmethylated patients, chemotherapy with Temozolomide was avoided. Here, we made a comprehensive evaluation of the neurooncological community suggestions regarding GBM treatment in the pre-vaccine era of COVID-19 pandemic.
References
Peng L, Zagorac S, Stebbing J Managing patients with cancer in the COVID-19 era Eur J Cancer 2020:132:5-7
Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X COVID-19 in cancer patients: risk, clinical features, and management Cancer Biol Med 2020:17(3):519-527
Cazzato G, Foti C, Colagrande A et al Skin Manifestation of SARS-CoV-2: The Italian Experience J Clin. Med 2021:10:566
Delgado-López PD, Corrales-García EM Survival in glioblastoma: a review on the impact of treatment modalities Clin Transl Oncol 2016:18(11):1062-1071
Weinkove R, McQuilten ZK, Adler J et al Managing hematology and oncology patients during the COVID-19 pandemic: interim consensus guidance Med J Aust 2020:212(10):481-489
Pessina F, Navarria P, Bellu L, et al Treatment of patients with glioma during the COVID-19 pandemic: what we learned and what we take home for the future Neurosurg Focus 2020:49(6):E10
Weller M, Preusser M How we treat patients with a brain tumour during the COVID-19 pandemic ESMO Open 2020:4(Suppl 2):e000789
Bernhardt D, Wick W, Weiss SE, et al Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas [published online ahead of print, 2020 May 5] Neuro Oncol 2020:22(7):928-935
Mrugala MM, Ostrom QT, Pressley SM et al The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment Neurooncol Adv 2021:3(1):vdab035
Stupp R, Mason WP, van den Bent MJ, et al Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 2005:352(10):987-996
Perry JR, Laperriere N, O'Callaghan CJ, et al Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma N Engl J Med 2017:376(11):1027-1037
Pellerino A, Bruno F, Internò V, Rudà R, Soffietti R Current clinical management of elderly patients with glioma Expert Rev Anticancer Ther 2020:20(12):1037-1048
Gay HA, Santiago R, Gil B, et al Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients Pract Radiat Oncol 2019:9(5):305-321
Hegi ME, Stupp R. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma? Neuro Oncol 2015:17(11): 1425-1427
Kamson DO, Grossman SA The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic JAMA Oncol 2021:7(5):675-676
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Lancet 2020:395(10223):473-475
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Publisher
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
